EIT Health France announces winning start-ups of Headstart Funding Programme 2018

The winning start-ups received an additional €10 000 as support to develop their projects.

Six of eleven start-ups supported by the 2018 EIT Health France HeadStart Funding Programme have been selected to receive an additional €10 000 support to develop their projects.

On 10 December EIT Health France organised the final selection of the HeadStart Funding Programme. The 11 selected start-ups that received a €40 000 EIT Health Grant earlier this year, presented their funded projects to our jury panel to get in order to receive an additional grant.

The purpose of this hearing session was to evaluate their project as well as the attribution of the EIT Health grant.

Our jury evaluated the and utilisation of EIT Health grant so far and selected six projects that will receive an additional €10 000:

AP Advance – develops a patch-artificial pancreas gathering an interstitial glucose sensor, an innovative computing algorithm and an insulin pump into a light, affordable and wearable device for improved diabetes management. “We aim at restoring autonomy and insouciance for all insulin-requiring patients.

Fasteesh – Dental hygiene for the dependent and elderly people is bad, due to a lack of time and the correct technique from the caregivers, which leads to major health, nutrition and life quality issues for the patients. We have developed a dental-care device which makes it possible to brush teeth and dentures efficiently, easily and in ten seconds only.

ExactCure – a pioneer start-up offering a software solution to reduce the impact of inappropriate medications. Our Digital Twin simulates the efficacy and interactions of medicines in the body of a patient based on his/her personal characteristics. We help the patient to avoid under-doses, overdoses and drug interactions.

Inorevia – Develops and commercialises a new generation of lab instruments for biology and medicine, that involves breakthrough patented technologies to miniaturise reactional volumes, hence drastically reducing costs, time and manipulation necessary to perform next-generation bioassays and precision medicine.

PANDA GUIDE – Make use of augmented reality to revolutionise the autonomy of the blind, through immersive educative experiences.

Sinnovial – The SinnoTest device will be a personalised medicine-software platform focused on improving the management of inflammatory diseases in rheumatology (rheumatoid arthritis, etc.). From a simple blood sample, the SINNOTEST will predict the effectiveness of a treatment before its prescription based on the analysis of specifics biomarkers of the patient.